DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00003744
- Locations
- 🇺🇸
Lahey Clinic, Burlington, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT00005627
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT00047281
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 151
- Registration Number
- NCT00003966
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: CD 40
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT00020670
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 31
- Registration Number
- NCT00006107
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT00047294
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia
- Conditions
- Fanconi's Anemia
- First Posted Date
- 2000-08-04
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT00006127
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States